|
Tough choice: Pain or risk?
USA Today - Dec 22, 2004
... suffered since age 14 from a type of arthritis called ankylosing spondylitis. ... But Grech says she won't give up Celebrex unless its maker, Pfizer, ...
|
|
Merck Submits Arthritis Drug to FDA for Approval.
Free with registration - The Record - AccessMyLibrary.com - Jan 8, 2004
Approved in the late 1990s, Celebrex and Vioxx were celebrated as two of the ... That June, the company then said the FDA had asked for more data from the ...
|
|
|
|
FDA requests further safety data for Arcoxia
Pharmafocus - Nov 10, 2004
Merck has received an 'approvable' letter from the FDA for Arcoxia but will ... The approval may present an opportunity to Pfizer's Celebrex which earned ...
|
|
|
|
THIS MONTH'S HIGHLIGHTS
$1,320.00 - DATAMONITOR - Alacra Store - Aug 13, 2003
physical function in patients with ankylosing spondylitis. Amgen expects FDA approval for this indication later. this year. ...
|
|
LABELING FOR REMICADE, STRATTERA REVISED FOR LIVER RISKS
Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones - Dec 27, 2004
Centocor announced last week that the FDA approved a new indication for Remicade as a treatment for ankylosing spondylitis, an inflammatory condition of the ...
|
|
